| Market Cap | 1.64B | P/E | - | EPS this Y | -8.80% | Ern Qtrly Grth | - |
| Income | -53.89M | Forward P/E | -11.03 | EPS next Y | -45.60% | 50D Avg Chg | -6.00% |
| Sales | 144.75M | PEG | -0.75 | EPS past 5Y | - | 200D Avg Chg | 9.00% |
| Dividend | N/A | Price/Book | 5.39 | EPS next 5Y | 69.30% | 52W High Chg | -30.00% |
| Recommedations | 1.70 | Quick Ratio | 5.89 | Shares Outstanding | 53.76M | 52W Low Chg | 119.00% |
| Insider Own | 12.75% | ROA | -7.43% | Shares Float | 35.42M | Beta | 0.23 |
| Inst Own | 95.35% | ROE | -13.80% | Shares Shorted/Prior | 4.75M/5.03M | Price | 34.20 |
| Gross Margin | 91.70% | Profit Margin | -37.23% | Avg. Volume | 563,691 | Target Price | 83.20 |
| Oper. Margin | -127.79% | Earnings Date | - | Volume | 436,561 | Change | 0.06% |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Cantor Fitzgerald | Overweight | Sep 9, 24 |
| Cantor Fitzgerald | Overweight | Sep 3, 24 |
| Needham | Buy | Aug 9, 24 |
| Canaccord Genuity | Buy | Jul 22, 24 |
| Truist Securities | Buy | Jun 18, 24 |
| Piper Sandler | Overweight | May 31, 24 |
| Stifel | Buy | May 15, 24 |
| Evercore ISI Group | Outperform | May 14, 24 |
| HC Wainwright & Co. | Buy | May 13, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Jan 02 | Option | 0.00 | 16,519 | 25,457 | 01/04/24 | |
| Gilson Michelle | Chief Financial Offi.. Chief Financial Officer | Jan 02 | Option | 0.00 | 15,339 | 24,824 | 01/04/24 | |
| Elghandour Rami | See Remarks See Remarks | Jan 02 | Option | 0.00 | 53,097 | 89,266 | 01/04/24 | |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Aug 04 | Sell | 35.38 | 3,000 | 106,140 | 7,795 | 08/07/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Aug 04 | Option | 15 | 3,000 | 45,000 | 10,795 | 08/07/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Jul 03 | Sell | 31.75 | 3,000 | 95,250 | 7,795 | 07/05/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Jul 03 | Option | 15 | 3,000 | 45,000 | 10,795 | 07/05/23 |
| Elghandour Rami | See Remarks See Remarks | May 31 | Sell | 44.2688 | 2,600 | 115,099 | 36,169 | 06/02/23 |
| Gilson Michelle | Chief Financial Offi.. Chief Financial Officer | May 23 | Sell | 42.29 | 14,704 | 621,832 | 9,485 | 05/25/23 |
| Gilson Michelle | Chief Financial Offi.. Chief Financial Officer | May 23 | Option | 0 | 22,428 | 24,189 | 05/25/23 | |
| Carroll Jill | Director Director | May 11 | Sell | 45.58 | 638,417 | 29,099,047 | 2,828,394 | 05/15/23 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner 10% Owner | May 11 | Sell | 45.58 | 1,012,833 | 46,164,928 | 1,658,780 | 05/15/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | May 05 | Sell | 45.0017 | 1,200 | 54,002 | 10,492 | 05/08/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Apr 03 | Sell | 30.9 | 3,000 | 92,700 | 15,589 | 04/04/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Apr 03 | Option | 15 | 3,000 | 45,000 | 18,589 | 04/04/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Feb 07 | Sell | 30.77 | 6,966 | 214,344 | 15,589 | 02/09/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Feb 07 | Option | 0 | 22,555 | 22,555 | 02/09/23 | |
| Elghandour Rami | See Remarks See Remarks | Feb 07 | Sell | 30.77 | 31,442 | 967,470 | 38,769 | 02/09/23 |
| Elghandour Rami | See Remarks See Remarks | Feb 07 | Option | 0 | 70,211 | 70,211 | 02/09/23 | |
| SANDELL SCOTT D | 10% Owner 10% Owner | Dec 23 | Sell | 31.67 | 390 | 12,351 | 12/27/22 | |
| SANDELL SCOTT D | 10% Owner 10% Owner | Dec 20 | Sell | 30.74 | 179 | 5,502 | 12/22/22 | |
| New Enterprise Associates 15,... | 10% Owner 10% Owner | Jun 21 | Buy | 16.00 | 312,500 | 5,000,000 | 6,745,262 | 06/23/22 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 1,666,667 | 25,000,005 | 2,033,196 | 02/10/22 |
| New Enterprise Associates 15,... | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 1,583,333 | 23,749,995 | 6,432,762 | 02/09/22 |
| Carroll Jill | Director Director | Feb 08 | Buy | 15 | 1,666,667 | 25,000,005 | 2,033,196 | 02/09/22 |
| Novo Holdings A/S | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 833,333 | 12,499,995 | 4,016,878 | 02/09/22 |